Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials

Rice, Dennis A.K.; Kaniga, Koné; Lee, Michael; Redman, Rebecca

doi:10.1016/j.ijantimicag.2012.12.016

Cited by 6 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The broad-spectrum carbapenems-doripenem, imipenemcilastatin, and meropenem-have been recommended for the treatment of patients with IAI in previous guidelines as they have become available [1,2,4,5]. Doripenem was compared with meropenem for the treatment of adult patients with IAI in two large RCTs (Supplementary Table I; see online supplementary material at www.liebertpub.com/overview/ surgical-infections/53/) [288,289]. No significant differences were observed in clinical success rates between the two carbapenems.…”

Section: 2mentioning

confidence: 99%

“…Meropenem has also been evaluated extensively in RCTs, including eight published since 2000 (Supplementary Table I; see online supplementary material at www.liebertpub.com/ overview/surgical-infections/53/) [263,264,274,275,[288][289][290]292]. There were no statistically significant differences in outcomes between meropenem and comparators in these recent trials.…”

Section: 2mentioning

confidence: 99%

“…Indirect evidence in support of a switch to oral antibiotic agents has come from additional RCTs in which patients were allowed to receive oral agents [215,217,229,[245][246][247]249,251,288,289,301,377]. It should be noted that many of these trials allowed for prolonged antimicrobial therapy, well beyond the previous recommendation of a maximum four to seven days of total antimicrobial therapy [2,4] or the current recommendation of a maximum of four days in adult patients or five days in pediatric patients (Sections 10 and 13).…”

Section: H Tigecyclinementioning

confidence: 99%

See 2 more Smart Citations

The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection

Mazuski

Tessier

May

et al. 2017

Surgical Infections

456

426

View full text Add to dashboard Cite

show abstract

Section: 2mentioning

confidence: 99%

Section: 2mentioning

confidence: 99%

Section: H Tigecyclinementioning

confidence: 99%

See 1 more Smart Citation

The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection

Mazuski

Tessier

May

et al. 2017

Surgical Infections

456

426

View full text Add to dashboard Cite

show abstract

“…In vitro activity of doripenem is reported to be comparable to those of other carbapenems [ 5 6 7 8 9 ]. In addition, regarding clinical outcomes of complicated urinary tract infection, complicated intra-abdominal infection, nosocomial pneumonia, and bacteremia cases, doripenem shows similar effectiveness compared with other carbapenems [ 16 17 18 ]. These data suggest that doripenem is a valuable antimicrobial treatment option against serious GNB infections.…”

Section: Discussionmentioning

confidence: 99%

In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center

et al. 2015

View full text Add to dashboard Cite

BackgroundDoripenem is the most recently introduced antimicrobial agent of the carbapenem class. It is a valuable therapeutic option in the context of increasing antimicrobial resistance to imipenem and meropenem among gram-negative bacilli (GNB) clinical isolates. However, clinicians are usually reluctant to prescribe doripenem, because susceptibility to doripenem is not automatically reported by most clinical laboratories and the in vitro activity of doripenem against clinically significant GNB isolates remains uncertain.Materials and MethodsWe investigated the in vitro antibacterial activity of doripenem in GNB blood isolates in a tertiary care center. Over a period of 10 months, 212 adult bacteremia cases were treated at the study hospital. Doripenem susceptibility testing was performed for the 212 blood isolates by the disk diffusion method, and clinical data were collected.ResultsAmong the blood isolates, the rate of doripenem resistance (7.5%) was lower than that of imipenem (12.9%) or other anti-GNB antimicrobial agents, except amikacin (2.1%). Almost all imipenem-susceptible GNB blood isolates (181/182, 99.5%) were susceptible to doripenem. Whereas doripenem resistance was rarely observed in Enterobacteriaceae (2/181, 1.1%), it was frequently observed in patients with non-fermentatative GNB (12/27, 44.4%), hospital-acquired infections (7/27, 25.9%), and pneumonia (11/49, 22.4%).ConclusionDoripenem exhibited more potent in vitro activity against GNB blood isolates than other anti-GNB antimicrobial agents in a tertiary care center where it was infrequently prescribed compared with other carbapenems. However, its clinical utility may be limited due to the increasing number of carbapenem-resistant non-fermentative GNB infections.

show abstract

“…An analysis of patients with concurrent bacteremia and either nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection from six Phase III clinical trials demonstrated similar cure rates and clearance of bacteremia in patients treated with doripenem and comparator agents. 4 In the US CAPITAL (Carbapenem Antimicrobials Pseudomonas Isolate Testing At regional Locations) 2010 surveillance program, doripenem was found to be the most active carbapenem agent against P. aeruginosa (88.6% isolates susceptible versus 78.1% for imipenem and 84.6% for meropenem). 5 …”

Section: Introductionmentioning

confidence: 99%

The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis

Wieczorek¹,

Tokarz²,

Gaszyński³

et al. 2014

DDDT

View full text Add to dashboard Cite

Doripenem is a novel wide-spectrum antibiotic, and a derivate of carbapenems. It is an ideal antibiotic for treatment of serious nosocomial infections and severe sepsis for its exceptionally high efficiency and broad antibacterial spectrum of action. Doripenem is eliminated mainly by the kidneys. In cases of acute kidney injury, dosing of doripenem depends on creatinine clearance and requires adjustments. Doripenem is eliminated during hemodialysis because its molecular weight is 300–400 Da. The aim of this study was to establish the impact of continuous renal replacement therapy (CRRT) slow low-efficiency dialysis (SLED) on doripenem serum concentrations in a population of intensive-therapy patients with life-threatening infections and severe sepsis. Ten patients were enrolled in this observational study. Twelve blood samples were collected during the first administration of doripenem in a 1-hour continuous infusion while CRRT SLED was provided. Fluid chromatography was used for measurement of the concentration of doripenem in serum. In all collected samples, concentration of doripenem was above the minimum inhibition concentration of this antibiotic. Based on these results, we can draw the conclusion that doripenem concentration is above the minimum inhibition concentration throughout all of CRRT. The dosing pattern proposed by the manufacturer can be used in patients receiving CRRT SLED without necessary modifications.

show abstract

Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials

Cited by 6 publications

References 15 publications

The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection

The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection

In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center

The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis

Contact Info

Product

Resources

About